IPP Bureau

USFDA clears IND application for an intranasal RSV vaccine
USFDA clears IND application for an intranasal RSV vaccine

By IPP Bureau - March 29, 2022

The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers

Carestream Health India showcases two new products at IRIA
Carestream Health India showcases two new products at IRIA

By IPP Bureau - March 29, 2022

As a partner with IRIA, the company had a significant booth presence on-ground during the conference.

Lawrence Berkeley lab offers trial kit for CRAGE Genome Engineering Tool
Lawrence Berkeley lab offers trial kit for CRAGE Genome Engineering Tool

By IPP Bureau - March 29, 2022

Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products

Alembic Pharma acquires 100% stake in Aleor Dermaceuticals
Alembic Pharma acquires 100% stake in Aleor Dermaceuticals

By IPP Bureau - March 29, 2022

The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic

University of Glasgow’s research centre to be named Mazumdar-Shaw Advanced Research Centre
University of Glasgow’s research centre to be named Mazumdar-Shaw Advanced Research Centre

By IPP Bureau - March 29, 2022

John Shaw, who is a Glasgow University graduate, along with his wife Kiran Mazumdar-Shaw had gifted US $ 7.5 million to the university in July 2019

Qure.ai raises US $ 40 million from healthcare investors Novo Holdings and HealthQuad
Qure.ai raises US $ 40 million from healthcare investors Novo Holdings and HealthQuad

By IPP Bureau - March 29, 2022

The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development

USFDA approves EUA for second booster dose of Moderna
USFDA approves EUA for second booster dose of Moderna

By IPP Bureau - March 29, 2022

50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age

AbbVie to showcase neuroscience portfolio at AAN 2022 annual meeting
AbbVie to showcase neuroscience portfolio at AAN 2022 annual meeting

By IPP Bureau - March 29, 2022

AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia

Solvay partners with Mitsubishi Chemical to recycle end-of-life medical components
Solvay partners with Mitsubishi Chemical to recycle end-of-life medical components

By IPP Bureau - March 29, 2022

New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.

Govt signs agreement with Sapigen Biologix to develop two vaccines
Govt signs agreement with Sapigen Biologix to develop two vaccines

By IPP Bureau - March 28, 2022

Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project

Metropolis recognises medical students with scholarship grants and awards
Metropolis recognises medical students with scholarship grants and awards

By IPP Bureau - March 28, 2022

Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India

Tarlige tablets approved in Japan for treatment of patients with neuropathic pain
Tarlige tablets approved in Japan for treatment of patients with neuropathic pain

By IPP Bureau - March 28, 2022

In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP

EU approves Evusheld to prevent Covid-19
EU approves Evusheld to prevent Covid-19

By IPP Bureau - March 28, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months

EU and European Disability Forum laud efforts of Sightsavers in India
EU and European Disability Forum laud efforts of Sightsavers in India

By IPP Bureau - March 28, 2022

This targeted capacity-building and advocacy project in 15 districts and 5 states of India has facilitated the certification of disability for 11,152 people, provided disability pensions to 8,144 people and supported the issuing of voter IDs to 8,450 people with disabilities

Free guide to Colorectal Cancer Screening now available in Hindi
Free guide to Colorectal Cancer Screening now available in Hindi

By IPP Bureau - March 28, 2022

Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer

Latest Stories

Interviews

Packaging